Immunovative Therapies to Present at Biotech Showcase™ 2019 in San Francisco

JERUSALEM, Dec. 10, 2018 /PRNewswire/ -- Immunovative Therapies, Ltd. today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9 at the Hilton San Francisco Union Square.

Dr. Michael Har-Noy, Founder and CEO, will present at Biotech Showcase™ as follows:

Date: Monday, January 7, 2019

Time: 4:45pm

Room: Franciscan D (Ballroom Level)

Venue: Hilton San Francisco Union Square Hotel, 333 O'Farrell Street, San Francisco, CA (United States)

Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference that provides private and public biotechnology and life sciences companies with an opportunity to present to investors and executives during the course of one of the industry's largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.

Immunovative Therapies, Ltd. (ITL) is a private Israeli company that develops next generation immunotherapy treatments for cancer. The active ingredients in these treatments are derived from the living immune cells of healthy blood donors.

The company's platform technology, called the Mirror Effect^®, enables development of anti-tumor immunity customized to a patient and down regulation of the tumor's ability to evade the immune response in an "off-the-shelf" format. Mirror Effect^® is protected by over 200 issued patents worldwide.

The Company has three next generation products that have completed Phase II clinical development. These products have been shown to change metastatic tumors from "cold" to "hot," resulting in tumor reduction and life extension. The lead product, StimVax^®, is being advanced to Phase IIb clinical trials in metastatic colorectal cancer in the USA and in advanced/metastatic hepatocellular carcinoma in Southeast Asia.

ITL has formed a wholly-owned subsidiary, Mirror Biologics, Inc., in the USA to develop proprietary automated, closed, sterile bioreactor systems for the mass production of living cell therapies. This automated production system will produce StimVax^® at costs that are "affordable to the masses".

"We are honored to have been selected to present at the Biotech Showcase," said Dr. Michael Har-Noy, founder and CEO "This will be an opportunity for us to present our novel immunotherapy products, compelling Phase II data and our vision for providing an affordable, minimally toxic and effective treatment option to patients suffering from metastatic cancer. We look forward to meeting with investors, partners and collaborators to discuss joining with us to advance our products to commercialization."

"We are delighted that Immunovative Therapies will be presenting at Biotech Showcase this year," added Sara Demy-Colton, CEO of Demy-Colton. "Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal."

ABOUT IMMUNOVATIVE THERAPIES

Immunovative Therapies is a private Israeli company developing affordable therapeutic cancer vaccine products. Immunovative has GMP production facilities in Jerusalem, an internal CRO and blood donor/processing center in Phoenix, AZ USA and a site management organization in Thailand. Mirror Biologics is a wholly-owned subsidiary of Immunovative Therapies based in the USA. Mirror is developing automated, centrally-controlled blood processing and bioreactor production systems. www.immunovative.com

Contacts

Jackson Carpenter, Public Relations

Email: [email protected]

Phone: 1-415-659-1642

SOURCE Immunovative Therapies, Ltd.